her2-low expression in breast cancer
Published 2 years ago • 310 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:36
is her2-low a distinct subtype of breast cancer?
-
1:40
her2-low is not a distinct subtype in inflammatory breast cancer
-
2:05
latest news in her2-low breast cancer
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
1:33
questions remaining in the field of her2-low breast cancer
-
2:13
remaining questions surrounding her2-low breast cancer – how low can you go?
-
1:09
the exciting new field of her2-low breast cancer
-
4:15
debbrah: t-dxd in her2 or her2-low advanced breast cancer with cns involvement
-
0:46
biological behaviour of her2-low bc is dependent on hr expression
-
1:05
efficacy of trastuzumab deruxtecan in her2-low metastatic breast cancer
-
4:01
trastuzumab deruxtecan: a promising agent for treating her2-low breast cancer?
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
0:56
her2-low status as a therapeutic target in advanced breast cancer
-
0:32
highlights in her2-low breast cancer at sabcs 2022
-
1:10
the evolution of her2-low-positive breast cancer as a clinical subtype
-
0:56
remaining questions on the management of her2-low breast cancer
-
0:45
the evolution of her2-low breast cancer from primary to recurrence
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer